Inmune Bio, Inc. (INMB): Shareholders' Equity
$23.52M
As of 2025-12-31
$20.36M
As of 2026-06-30
-26.9%
3-year compound annual growth
-9.5%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $23.52M | -26.7% | 2026-03-30, Balance as of period end |
| 2024-12-31 | $32.10M | -14.0% | 2026-03-30, Balance as of period end |
| 2023-12-31 | $37.34M | -37.9% | 2025-03-27, Balance as of period end |
| 2022-12-31 | $60.10M | -25.1% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $80.22M | +107.0% | 2023-03-02, Balance as of period end |
| 2020-12-31 | $38.75M | +64.1% | 2022-03-03, Balance as of period end |
| 2019-12-31 | $23.61M | +42.7% | 2021-03-04, Balance as of period end |
| 2018-12-31 | $16.54M | -8.6% | 2020-03-11, Balance as of period end |
| 2017-12-31 | $18.10M | n/a | 2019-03-29, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Inmune Bio, Inc. (INMB) | 2025-12-31 | $23.52M | -26.7% |
| Entera Bio Ltd. (ENTX) | 2025-12-31 | $13.10M | +62.1% |
| AIM ImmunoTech Inc. (AIM) | 2025-12-31 | -$9.78M | n/m |
| Senti Biosciences Holdings, Inc. (SNTI) | 2025-12-31 | $5.59M | -78.2% |
| VivoSim Labs, Inc. (VIVS) | 2026-03-31 | -$1.10M | n/m |
| Zivo Bioscience, Inc. (ZIVO) | 2024-12-31 | -$514.9K | n/m |
| aTYR PHARMA INC (ATYR) | 2025-12-31 | $67.48M | -3.6% |
| Creative Medical Technology Holdings, Inc. (CELZ) | 2025-12-31 | $7.51M | +18.5% |
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | $45.39M | -45.3% |
Compare INMB, ENTX, AIM, SNTI side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗